Featured Research

from universities, journals, and other organizations

'Designer Estrogen' Identified As Potential MS Drug

Date:
August 28, 2007
Source:
University of California - Los Angeles
Summary:
While people with multiple sclerosis have many choices for anti-inflammatory drugs to help prevent flare-ups of their physical symptoms, no medication exists to stop MS from causing degeneration of the brain and spinal cord. Now a study finds that a new form of estrogen protects the brain without increasing the risk of hormone-induced cancers of the breast and uterus.

Healthy spinal cord tissue (left) shows a similar number of neurons (magnified in red) as MS-infected spinal cord tissue (right) in mice that have been treated with a specific form of estrogen. Less neurons are found in the spinal cords of mice whose disease went untreated (center).
Credit: Seema Tiwari-Woodruff/UCLA

UCLA scientists have found the first evidence that a specific form of estrogen can protect the brain from degeneration yet not increase the risk for estrogen-induced cancers of the breast and uterus. The study took place in mice infected with the animal equivalent of multiple sclerosis.

While people with MS have many choices for anti-inflammatory drugs to help prevent flare-ups of their physical symptoms, no medication exists to stop the disorder from causing degeneration of the brain and spinal cord. The UCLA findings offer potential for a "designer estrogen" that doctors could prescribe in higher doses without increasing a patient's cancer risk, as well as a potent MS cocktail blending the hormone with a standard anti-inflammatory treatment.

This form of estrogen also offers a new weapon for combating brain degeneration caused by Alzheimer's, Parkinson's, Lou Gehrig's disease, spinal cord injury and even normal aging. Finally, men may be able to use it without fear of developing the feminine side effects often produced by standard estrogen treatments.

Researchers Dr. Rhonda Voskuhl, Jack H. Skirball Chair in Multiple Sclerosis Research and professor of neurology; and Seema Tiwari-Woodruff, assistant professor of neurology are both from the UCLA Multiple Sclerosis Program at the David Geffen School of Medicine.

The National Institute of Neurological Disorders and Stroke, National Institute of Allergy and Infectious Diseases and National Multiple Sclerosis Society supported the research.

The study appears in the Aug. 27 -- 31 online edition of the Proceedings of the National Academy of Sciences.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Los Angeles. "'Designer Estrogen' Identified As Potential MS Drug." ScienceDaily. ScienceDaily, 28 August 2007. <www.sciencedaily.com/releases/2007/08/070827174327.htm>.
University of California - Los Angeles. (2007, August 28). 'Designer Estrogen' Identified As Potential MS Drug. ScienceDaily. Retrieved July 21, 2014 from www.sciencedaily.com/releases/2007/08/070827174327.htm
University of California - Los Angeles. "'Designer Estrogen' Identified As Potential MS Drug." ScienceDaily. www.sciencedaily.com/releases/2007/08/070827174327.htm (accessed July 21, 2014).

Share This




More Health & Medicine News

Monday, July 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins